# A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

> **NCT01421472** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 196 (actual)

## Conditions studied

- ER Positive, Her2 Negative Breast Cancer Patients
- Triple Negative Breast Cancer Patients

## Interventions

- **DRUG:** MM-121
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01421472
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2016-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421472, "A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01421472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*